Lercanidipine: A review of its use in hypertension

Drugs

Volumn 60, Issue 5, 2000, Pages 1123-1140

  McClellan, Karen J ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; CAPTOPRIL; CARBAMAZEPINE; CIMETIDINE; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ERYTHROMYCIN; FELODIPINE; FLUOXETINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; ITRACONAZOLE; KETOCONAZOLE; LERCANIDIPINE; METILDIGOXIN; METOPROLOL; MIDAZOLAM; NIFEDIPINE; NITRENDIPINE; PHENYTOIN; R 75; RIFAMPICIN; UNINDEXED DRUG;

ANKLE EDEMA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; FLUSHING; HEART PALPITATION; HUMAN; HYPERTENSION; NEUROTOXICITY; NONHUMAN; REVIEW;

EID: 0033673242     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060050-00009     Document Type: Review

References (59)

1. Dual mode of action of dihydropyridine calcium antagonists: A role for nitric oxide
2. How to use calcium antagonists in hypertension: Putting the JNC-VI guidelines into practice
3. The classification of calcium antagonists and their selection in the treatment of hypertension: A reappraisal
4. Lercanidipine: Short plasma half-life, long duration of action: A molecular model to rationalize its pharmacokinetic properties
5. In vitro calcium antagonist activity of lercanidipine and its enantiomers
6. Antihypertensive activity of lercanidipine and its enantiomers in animal models
7. Hemodynamic effects and power spectral analysis of heart rate and arterial pressure variabilities induced by lercanidipine and its enantiomers in conscious dogs
8. Lercanidipine: A novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity
9. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine
10. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues
11. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers
12. Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits
13. Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits
14. Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes
15. Influence of pharmacological treatment on the kidney of spontaneously hypertensive rats: A histochemical study
16. Glial-fibrillary acidic protein immunoreactive astrocytes in the brain of spontaneously hypertensive rats: Sensitivity to pharmacological treatment. 28th National Congress of the Italian Society of Histochemistry
17. Effects of lercanidipine, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats
18. Efficacy of lercanedipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract]
19. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril
20. Lercanidipine, a new calcium antagonist, does not affect cardiac potassium channels of animal and human ventricular myocytes
21. Haemodynamic effects of lercanidipine in a anaesthetized open-chest dogs
22. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: Is calcium entry involved?
23. Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension
24. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats
25. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: A randomized, double-blind pilot study
26. Different oedematigenous potential of lercanedipine and nifedipine in hypertensive patients
27. Clinical pharmacokinetics of lercanidipine
28. Lercanidipine plasma levels monitoring in patients. Pharmacokinetic contribution to the study Rec 15/2375-RIC1-0047: Dose finding study with lercanidipine in angina pectoris
29. Effect of lercanidipine on CYP2D6 and CYP3A4 activities: In vitro/in vivo correlation
30. Effect of lercanidipine on CYP2D6 and CYP3A4 activities: In vitro/in vivo correlation [abstract]
31. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension
32. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension
33. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension
34. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study
35. Active dose findings for lercanidipine in a double-blind, placebo-controlled design in patients with mild to moderate hypertension
36. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements
37. Efficacy and tolerability of lercanidipine once a day versus placebo in mild to moderate arterial hypertension
38. Long-term (12-month) treatment with lercanidipine in patients with mild to moderate hypertension
39. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double-blind controlled study
40. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study
41. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: A comparative study with slow-release nifedipine
42. Double-blind, crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension
43. Antihypertensive efficacy and tolerability of lercanidipine compared with candesartan, alone or in combination, in cases of mild to moderate essential hypertension
44. Comparative evaluation of the antihypertensive efficacy and tolerability of lercanidipine and irbesartan
45. A multicenter randomized, double-blind trial of the efficacy and safety of lercanidipine in patients with mild to moderate essential hypertension, uncontrolled on hydrochlorothiazide
46. Evaluation of the effects of monotherapy with lercanidipine 10, 20 and 30 mg compared with placebo on glucose homeostasis in patients with type II diabetes mellitus with mild-moderate essential hypertension
47. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: Current experience with lercanidipine
48. Lercanidipine: Experience in the daily clinical practice
49. Pharmacovigilance study of hypertensives with mild to moderate hypertension treated with lercanidipine
50. The use of lercanidipine can improve the individual tolerability to dihydropyridine calcium blockers in hypertensive patients
51. Blood pressure screening, management and control in England: Results from the health survey for England 1994
52. 1999 Heart and Stroke Statistical Update
53. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension
54. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
55. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
56. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
57. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study